|[January 09, 2014]
Law Offices of Howard G. Smith Announces Investigation on Behalf of Investors of Aegerion Pharmaceuticals, Inc.
BENSALEM, Pa. --(Business Wire)--
Law Offices of Howard G. Smith announces that it is investigating
potential claims on behalf of investors of Aegerion Pharmaceuticals,
Inc. ("Aegerion" or the "Company") (NASDAQ:AEGR) concerning possible
violations of federal securities laws. The investigation focuses on
certain statements issued by Aegerion concerning the Company's business,
operations and financial prospects. Please contact Law Offices of Howard
G. Smith to discuss this matter or other potential claims if you are a
long-term shareholder of Aegerion.
Aegerion is a biopharmaceutical company, engaged in the development and
commercialization of novel therapeutics to treat debilitating and fatal
rare diseases in the United States. The Company's lead product, Juxtapid
(lomitapide) capsules, is an adjunct to a low-fat diet and other
lipid-lowering treatments in patients with homozygous familial
hypercholesterolemia - a rare genetic dsease that impairs the function
of the receptor responsible for removing low-density lipoprotein
cholesterol from the blood.
The investigation is related to the Company's January 9, 2014,
disclosure that Aegerion has received a subpoena from the United States
Department of Justice, represented by the U.S. Attorney's Office in
Boston, Massachusetts, requesting documents regarding the Company's
marketing and sale of Juxtapid in the United States. According to an
article published that same day by Bloomberg (News - Alert) News, the Company's
chief executive officer received a warning letter from the Food and
Drug Administration in November, stating that the CEO's comments in an
interview on CNBC "provide evidence that Juxtapid is intended for new
uses, for which it lacks approval and for which its labeling does not
provide adequate directions for use."
If you purchased Aegerion stock and still hold those shares, if you have
information or would like to learn more about these claims, or if you
have any questions concerning this announcement or your rights or
interests with respect to these matters, please contact Howard G. Smith,
Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite
112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll
Free at (888) 638-4847, or by email to firstname.lastname@example.org,
or visit our website at www.howardsmithlaw.com.
[ Back To Technology News's Homepage ]